BVS — Bioventus Inc.

Bioventus Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: $132 million, a 7% increase year-over-year.
• Adjusted EBITDA: $24 million, up 24% from the previous year, with an adjusted EBITDA margin of 18%, an increase of 260 basis points.
• Adjusted EPS: $0.15, nearly double the $0.08 reported in Q1 2025.
• Cash Flow from Operations: $9 million, a $28 million increase compared to the prior year, marking the largest cash flow from operations in Q1 since going public.
• Debt: $272 million in outstanding debt, reduced by $22 million during the quarter.

2. Strategic Updates and Business Highlights

• Investment Focus: Bioventus is prioritizing investments in growth drivers such as PNS (Peripheral Nerve Stimulation), PRP (Platelet-Rich Plasma), Ultrasonics, and International segments.
• Sales and Marketing Expansion: Increased investment in commercial teams, marketing, and physician training programs to enhance product awareness and support.
• Leadership Addition: Megan Rosengarten appointed as General Manager for PNS, bringing experience in launching and scaling medical device businesses.
• Growth Drivers: Strong performance in Pain Treatments (8% growth), Surgical Solutions (6% growth), and Restorative Therapies (5% growth). International revenue grew 17%, with a constant currency growth of 11%.

3. Forward Guidance and Outlook

• Adjusted EPS Guidance: Increased to $0.75 - $0.79, up from previous guidance of $0.73 - $0.77.
• Cash Flow Guidance: Expected to range between $84 million and $89 million, a $2 million increase from prior guidance.
• Revenue Guidance: Reaffirmed at $600 million to $610 million for 2026, with expectations of accelerating growth in the second half of the year.

4. Bad News, Challenges, or Points of Concern

• Inventory Levels: Declining distributor inventory levels impacted volume growth, which could pose challenges in maintaining momentum.
• Market Variability: The favorable rebate adjustment was a one-time occurrence, and similar variability is not expected moving forward.
• Surgical Solutions Growth: Growth in the Surgical segment was below initial expectations, though management anticipates a ramp-up in growth rates later in the year.

5. Notable Q&A Insights

• Rebate Impact: Management clarified that the favorable rebate was not anticipated in timing, and it will not be a recurring factor.
• New Product Launches: Early feedback on PNS and PRP is positive, with expectations for growth to accelerate as investments ramp up.
• Ultrasonics Training: Increased emphasis on surgeon training and education is a key focus for driving growth in the Ultrasonics segment.
• Future Disclosure: Management indicated a willingness to provide more detailed metrics on PNS and PRP performance later in the year as data becomes available.

Overall, Bioventus reported a strong start to 2026, with solid financial performance and strategic investments aimed at driving future growth, despite some challenges in inventory management and segment-specific growth expectations.